The melanocortin family
MT-II is one member of a growing melanocortin family, and seeing it in context is the best way to understand both its…
Where MT-II sits, and where the science went next
MT-II is one member of a growing melanocortin family, and seeing it in context is the best way to understand both its appeal and its obsolescence. This unit compares MT-II with its relatives and its real alternatives, then looks at the selective, approved drugs that represent where melanocortin science actually went.
The throughline is a hopeful one: the messy, non-selective research compound pointed the way, and the field answered with cleaner, tested, approved molecules. MT-II is best understood as a stepping stone the science has already stepped past.
Key terms
The melanocortin family side by side
MT-II is easiest to understand next to its relatives. The three Melanotan-era peptides differ in selectivity and approval status, and lining them up shows exactly what made MT-II distinctive and what made it dispensable.
The column that matters is the last one. Afamelanotide reaches patients as an implant for one rare disease. Bremelanotide reaches them at 1.75 mg subcutaneously, for one diagnosis, after two phase 3 trials that randomized 1,267 women. In both cases the exposure is bounded and somebody measured what it costs. MT-II has neither a bounded dose nor a measured cost, which is why it sits alone in the unapproved column. And in neither case does the approved product's record say anything about MT-II.
AdvancedA bounded exposure, by one route or another
A drug reaches approval when somebody can say what a defined exposure does. Afamelanotide does that with an implant for one rare disease; bremelanotide does it with a fixed subcutaneous dose, one diagnosis, and two phase 3 trials that measured the result. MT-II has no bounded exposure at all: no approved dose, no ceiling, no trial that measured what any regimen does, and no published pharmacokinetics to reason from. That is the difference the grid is really showing, and it is about what was measured rather than about receptor chemistry.